Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study

Abstract Background Neoadjuvant short-course radiotherapy (SCRT) followed by camrelizumab and chemotherapy has shown an encouraging pathological complete response rate (48.1%, primary endpoint) in patients with locally advanced rectal cancer (LARC). Here, we present the 3-year survival outcomes. Met...

Full description

Bibliographic Details

Published in:	BMC Medicine
Main Authors:	Zhenyu Lin, Peng Zhang, Ming Cai, Gang Li, Tao Liu, Kailin Cai, Jing Wang, Junli Liu, Hongli Liu, Weikang Zhang, Jinbo Gao, Chuanqing Wu, Linfang Wang, Zheng Wang, Zhiguo Hou, Hongyi Kou, Kaixiong Tao, Tao Zhang
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Subjects:	Locally advanced rectal cancer Neoadjuvant Short-course radiotherapy Camrelizumab Survival
Online Access:	https://doi.org/10.1186/s12916-025-04087-x